联邦制药发布公告,本公司董事会仅此宣布,拟根据本公司股东于2024年6月20日举行的本公司股东周年大会上授出的购回本公司普通股股份的一般授权(购回授权)行使其权力,斥资最多2亿港元以于适当时候于公开市场购回股份(建议股份购回)。本公司其后将注销所购回的股份。建议股份购回将以内部现金支付。董事会坚信目前本公司拥有稳健的财政状况,且认为建议股份购回符合本公司及股东的整体利益。建议股份购回及其后注销所...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.